Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Saxenda is a pure GLP-1 receptor agonist containing liraglutide, the same active ingredient as Victoza
- It was the first GLP-1 medication FDA-approved specifically for chronic weight management (December 2014)
- Saxenda is dosed daily by subcutaneous injection, in contrast to weekly options like Wegovy and Zepbound
- Mean weight loss in trials is about 5 to 8 percent of body weight, smaller than newer GLP-1 medications
- The adolescent indication (ages 12 to 17) was added in December 2020 based on SCALE Teens data
Direct answer
Yes, Saxenda is a GLP-1 medication. Its active ingredient is liraglutide, a glucagon-like peptide-1 receptor agonist. Saxenda is the higher-dose, obesity-indicated formulation of liraglutide, dosed up to 3.0 mg subcutaneously once daily. The lower-dose version (up to 1.8 mg daily) is sold as Victoza for type 2 diabetes. Both contain the same molecule; the differences are dose, titration schedule, and approved indication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The clean yes, with context
- Liraglutide at the molecular level
- Why daily injection instead of weekly
- How Saxenda and Victoza differ
- The SCALE clinical trial program
- The adolescent indication and SCALE Teens
- Saxenda dosing and titration
- Side effects and class warnings
- Saxenda vs newer weight-loss GLP-1 medications
- Where Saxenda still fits in 2026
- Contrary view: is Saxenda obsolete?
- Decision framework
- FAQ
- Sources
The clean yes, with context
Saxenda is unambiguously a GLP-1 medication. The active ingredient, liraglutide, activates only the GLP-1 receptor. There is no GIP component, no glucagon receptor component. This makes Saxenda a pure GLP-1 RA, like Wegovy and Victoza, distinct from dual agonists like Zepbound and Mounjaro.
Saxenda's place in the timeline matters. It was approved in December 2014, seven years before Wegovy. For most of the late 2010s, Saxenda was the only GLP-1 medication labeled specifically for obesity in the United States. The clinical experience accumulated during that period shaped how obesity specialists think about GLP-1 therapy.
When weekly GLP-1 medications arrived for obesity (Wegovy in 2021, Zepbound in 2023), Saxenda's market share contracted. Its daily-injection regimen and smaller weight-loss effect could not compete with weekly options that produced two to four times more weight loss. Saxenda still has a place in treatment, but no longer dominates the obesity GLP-1 market.
Liraglutide at the molecular level
Liraglutide is a 31 amino acid peptide based on human GLP-1. The molecule is 97 percent identical to native human GLP-1, with two modifications:
- An amino acid substitution at position 34 (Lys for Arg) that prevents binding to certain ubiquitin proteins
- A 16-carbon fatty acid chain attached at position 26 via a glutamic acid linker
The fatty acid chain binds to albumin in the blood, slowing the molecule's clearance. The combination of modifications extends the half-life to about 13 hours, compared with one to two minutes for native GLP-1.
This 13-hour half-life is the key constraint. It is long enough to support once-daily dosing but not long enough for weekly dosing. The successor molecules (semaglutide, dulaglutide) achieved much longer half-lives through more aggressive structural modifications, particularly more strongly albumin-binding fatty acid chains and additional protease resistance.
Liraglutide was developed by Novo Nordisk during the early 2000s. The lead investigator, Lotte Bjerre Knudsen, is now widely recognized for her role in bringing both liraglutide and semaglutide to market.
Why daily injection instead of weekly
The daily-injection regimen is determined by liraglutide's pharmacokinetics. The half-life of 13 hours means that without daily dosing, blood levels would fall below therapeutic concentrations within two to three days.
Daily injection has some advantages:
- Faster titration to therapeutic dose (4 weeks vs 16 weeks for Wegovy)
- Faster clearance if a complication requires discontinuation
- Daily injection becomes routine for some patients in the same way as daily oral medications
Daily injection has clear disadvantages:
- Higher behavioral burden for adherence
- More injection-related issues over time
- Less convenient for travel, work schedules, and varied routines
For most patients, the convenience of weekly injection outweighs the advantages of daily dosing. This is one of the main reasons Saxenda lost market share to Wegovy and Zepbound.
How Saxenda and Victoza differ
Both products contain liraglutide. The differences:
| Feature | Saxenda | Victoza |
|---|---|---|
| Approved indication | Chronic weight management | Type 2 diabetes; CV risk reduction in diabetes with CVD |
| Maximum dose | 3.0 mg daily | 1.8 mg daily |
| Titration schedule | Weekly increases to 3.0 mg | Weekly increases to 1.8 mg |
| Approved year | 2014 (adults); 2020 (adolescents) | 2010 |
| Pen design | Multi-dose disposable, calibrated for 3.0 mg | Multi-dose disposable, calibrated for 1.8 mg |
Patients on Saxenda 3.0 mg are receiving 67 percent more liraglutide per day than patients on Victoza 1.8 mg. The higher dose drives the larger weight-loss effect.
This dual-product structure mirrors what Novo Nordisk did later with semaglutide (Ozempic for diabetes at 2.0 mg weekly, Wegovy for obesity at 2.4 mg weekly). The pattern reflects both regulatory pathway design and commercial differentiation.
The SCALE clinical trial program
Saxenda's approval rested on the SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) clinical trial program:
SCALE Obesity and Prediabetes (Pi-Sunyer et al., New England Journal of Medicine 2015). Liraglutide 3.0 mg vs placebo in adults with obesity or overweight with prediabetes. Mean weight loss at 56 weeks: 8.0 percent on liraglutide vs 2.6 percent placebo. About 63 percent of patients on liraglutide lost at least 5 percent body weight.
SCALE Diabetes. Liraglutide 3.0 mg in adults with obesity and type 2 diabetes. Mean weight loss: 6.0 percent on liraglutide vs 2.0 percent placebo.
SCALE Maintenance. Liraglutide vs placebo after low-calorie-diet-induced weight loss. Patients who first lost weight on diet were randomized to liraglutide or placebo for maintenance. Liraglutide produced additional weight loss; placebo group regained weight.
SCALE Sleep Apnea. Liraglutide in adults with obesity and moderate-to-severe OSA. Improved apnea-hypopnea index correlated with weight loss.
Across the SCALE program, liraglutide consistently produced 5 to 8 percent weight loss in different populations, with the larger effects in non-diabetic populations.
The cardiovascular safety of liraglutide was established by the LEADER trial (Marso et al., New England Journal of Medicine 2016), which tested the diabetes dose (1.8 mg daily) in patients with type 2 diabetes and high cardiovascular risk. The result was a 13 percent reduction in major adverse cardiovascular events. This evidence base supported Victoza's cardiovascular indication. Saxenda did not undergo a similar cardiovascular outcome trial in obesity populations.
The adolescent indication and SCALE Teens
SCALE Teens (Kelly et al., New England Journal of Medicine 2020) tested liraglutide 3.0 mg in adolescents aged 12 to 17 with obesity. Mean BMI reduction at 56 weeks was 4.6 percent on liraglutide vs 0.2 percent on placebo. The trial supported the FDA's December 2020 approval of Saxenda for chronic weight management in adolescents 12 and older with body weight above 60 kg and BMI corresponding to obesity.
The adolescent approval was clinically important. At the time, Saxenda was one of the few medication options for adolescent obesity. The American Academy of Pediatrics 2023 guidelines included anti-obesity medications as part of comprehensive treatment for adolescents with obesity.
Wegovy was later approved for adolescents in December 2024, based on STEP TEENS data. As of May 2026, Saxenda and Wegovy were both approved for the adolescent population, with Wegovy producing larger weight-loss effects but requiring weekly rather than daily injection.
Saxenda dosing and titration
Saxenda is dosed once daily by subcutaneous injection. The titration schedule:
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5 onward: 3.0 mg daily (maintenance)
If a patient cannot tolerate the next planned dose, the prior dose may be maintained for an additional week or longer before another titration attempt. Some patients stabilize below 3.0 mg if they achieve clinical response or cannot tolerate the higher dose.
The Saxenda pen is a multi-dose disposable injector that delivers 0.6 to 3.0 mg per dose. Injection sites rotate among abdomen, thigh, and upper arm. Each pen contains 18 mg of liraglutide, providing 6 days of maintenance dosing at 3.0 mg.
Side effects and class warnings
The side-effect profile of Saxenda is the prototypical GLP-1 RA pattern:
- Nausea: about 39 percent of patients (high in trials, often during titration)
- Hypoglycemia: rare on Saxenda alone, common when combined with insulin or sulfonylureas
- Diarrhea: about 21 percent
- Constipation: about 19 percent
- Vomiting: about 16 percent
- Headache: about 14 percent
- Decreased appetite: often noted as desired effect
- Dyspepsia: about 10 percent
- Fatigue: about 8 percent
The boxed warning for Saxenda concerns medullary thyroid carcinoma, based on rodent data showing thyroid C-cell tumors. Saxenda is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Other warnings: acute pancreatitis, acute gallbladder disease, acute kidney injury (typically from dehydration), hypoglycemia in patients on insulin or insulin secretagogues, hypersensitivity reactions, diabetic retinopathy complications, increased heart rate, suicidal behavior and ideation (monitoring recommended), and pulmonary aspiration during anesthesia (consider perioperative discontinuation).
Saxenda vs newer weight-loss GLP-1 medications
The efficacy gap between Saxenda and newer obesity GLP-1 medications is substantial:
| Medication | Active ingredient | Dosing | Mean weight loss |
|---|---|---|---|
| Saxenda | Liraglutide | Daily | 5-8% |
| Wegovy | Semaglutide | Weekly | ~14.9% (STEP 1) |
| Zepbound | Tirzepatide | Weekly | ~22.5% (SURMOUNT-1) |
STEP 8 (Rubino et al., JAMA 2022) directly compared semaglutide 2.4 mg weekly with liraglutide 3.0 mg daily. Semaglutide produced significantly more weight loss: 15.8 percent vs 6.4 percent at 68 weeks. The result settled the head-to-head question and confirmed Wegovy's superiority over Saxenda for weight loss in adults.
The clinical implication is that patients who could tolerate either drug would typically lose more weight on Wegovy or Zepbound than on Saxenda. This explains the rapid shift in prescribing patterns after Wegovy's 2021 launch.
Where Saxenda still fits in 2026
Despite smaller effects than newer drugs, Saxenda remains useful in specific situations:
- Adolescents. Saxenda has been approved for ages 12 to 17 since 2020, with more accumulated pediatric experience than Wegovy (which received its adolescent indication in late 2024).
- Patients who prefer shorter-acting drugs. Daily dosing allows faster clearance if complications arise, which can be reassuring for first-time users of weight-loss medications.
- Patients with insurance coverage for Saxenda but not weekly options. Some plans cover Saxenda but require step therapy or fail before approving Wegovy or Zepbound.
- Patients with severe nausea on weekly drugs. The shorter half-life of liraglutide produces somewhat different nausea dynamics that some patients find more tolerable.
- Patients during pregnancy planning. Daily dosing allows quicker clearance if pregnancy occurs (GLP-1 RAs are not recommended during pregnancy across the class).
For most other patients, weekly GLP-1 medications or dual agonists are preferred.
Contrary view: is Saxenda obsolete?
Strong arguments can be made that Saxenda is no longer appropriate first-line therapy in 2026.
First, the efficacy difference is large. Patients on Saxenda lose roughly half as much weight as patients on Wegovy and about one-third as much as patients on Zepbound. Prescribing the less effective option without specific reason is hard to justify.
Second, the daily injection burden is significant. Patient adherence with daily injections is consistently lower than with weekly injections in real-world data. Suboptimal adherence further reduces the already-smaller effect.
Third, the cardiovascular evidence base is weaker. Liraglutide's CV benefit was demonstrated for the diabetes dose (Victoza 1.8 mg), not specifically for the obesity dose (Saxenda 3.0 mg). Wegovy has the SELECT cardiovascular indication that Saxenda does not.
Fourth, the cost has not declined to match the efficacy gap. Saxenda's list price remains substantial, while weekly options offer more weight loss for similar or slightly higher cost.
The counterargument: Saxenda has accumulated 12 years of post-marketing experience. The pediatric indication preceded Wegovy's by four years. Some patients have specific reasons to prefer daily dosing. The drug remains an option even if not first-line.
The reasonable position: Saxenda is no longer first-line therapy for most adult obesity patients but retains a niche role. Patients well-controlled on Saxenda can continue. New initiations typically use weekly options unless specific clinical reasons favor daily dosing.
Decision framework
If you are asking whether Saxenda is a GLP-1:
- Yes. Saxenda is a pure GLP-1 receptor agonist, the first one approved for obesity in the U.S.
- Daily injection differentiates it from weekly options like Wegovy.
If you are choosing between Saxenda and Wegovy:
- Wegovy produces more weight loss in head-to-head trials (STEP 8).
- Wegovy requires weekly injection vs Saxenda's daily injection.
- Wegovy has a cardiovascular indication from SELECT that Saxenda does not.
If you are considering Saxenda for an adolescent:
- Saxenda has been approved for ages 12 to 17 since 2020.
- Wegovy was approved for the same age group in December 2024.
- Both are reasonable options; choice depends on clinical fit and family preference.
If you are currently on Saxenda:
- Continuing makes sense if you tolerate it well and meet treatment goals.
- Switching to a weekly drug is also reasonable; discuss with your provider.
FAQ
Is Saxenda a GLP-1? Yes. Saxenda contains liraglutide, a pure GLP-1 receptor agonist.
What is Saxenda used for? Chronic weight management in adults with obesity or overweight with comorbidities, and in adolescents 12 to 17 with obesity.
Is Saxenda the same as Victoza? Same molecule (liraglutide). Different maximum dose (3.0 mg vs 1.8 mg daily), different approved indication (obesity vs diabetes).
How much weight do people lose on Saxenda? Mean 5 to 8 percent over 56 weeks in SCALE trials. Less than Wegovy or Zepbound.
Why is Saxenda dosed every day? Liraglutide has a 13-hour half-life. Daily dosing maintains therapeutic levels. Newer GLP-1 RAs have longer half-lives and allow weekly dosing.
Is Saxenda still prescribed? Yes, but at lower volume than before weekly weight-loss GLP-1s arrived. Specific patient populations still benefit from Saxenda.
When was Saxenda FDA-approved? December 23, 2014, for adults. December 2020 for adolescents 12 and older.
Who makes Saxenda? Novo Nordisk, based in Denmark. The same company makes Victoza, Ozempic, Wegovy, and Rybelsus.
What is the maximum dose of Saxenda? 3.0 mg daily by subcutaneous injection.
Does Saxenda work in adolescents? Yes. SCALE Teens showed about 4.6 percent BMI reduction at 56 weeks vs 0.2 percent placebo. The FDA approved the adolescent indication in December 2020.
How does Saxenda compare to Wegovy? Both contain GLP-1 receptor agonists from Novo Nordisk. Saxenda contains liraglutide (daily). Wegovy contains semaglutide (weekly). Wegovy produces significantly more weight loss in head-to-head trials.
Can I stop Saxenda after I reach my goal weight? Like other GLP-1 medications for obesity, stopping Saxenda typically leads to weight regain. Long-term use is generally required to maintain weight loss.
Sources
- FDA Prescribing Information. Saxenda (liraglutide). Updated 2024.
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
- Davies MJ et al. Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes (SCALE Diabetes). JAMA. 2015.
- Wadden TA et al. Weight Maintenance and Additional Weight Loss with Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance). International Journal of Obesity. 2013.
- Blackman A et al. Effect of Liraglutide 3.0 mg in Individuals with Obesity and Moderate or Severe Obstructive Sleep Apnea (SCALE Sleep Apnea). International Journal of Obesity. 2016.
- Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (SCALE Teens). New England Journal of Medicine. 2020.
- Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022.
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. 2023.
- Knudsen LB et al. Liraglutide: The Therapeutic Promise from Animal Models. International Journal of Clinical Practice. 2010.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that facilitates connections between users, independent licensed clinicians, and U.S.-based pharmacies. We do not own a pharmacy, employ providers, or manufacture medications. Clinical decisions belong to the prescribing clinician.
Compounded Medication Notice. Compounded liraglutide is rare and typically not the primary form of GLP-1 compounding. Compounded semaglutide and tirzepatide preparations from 503A pharmacies are not FDA-approved and are not equivalent to brand products like Saxenda, Wegovy, Ozempic, Mounjaro, or Zepbound.
Results Disclaimer. Trial averages reflect controlled study populations. Individual outcomes depend on dose tolerated, adherence, dietary habits, activity levels, baseline weight, and biological factors. Weight regain typically follows discontinuation of chronic obesity therapy.
Trademark Notice. Saxenda, Victoza, Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends has no affiliation with Novo Nordisk, Eli Lilly, AstraZeneca, Currax Pharmaceuticals, or any other manufacturer of these products.